International Stem Cell Corp (ISCO): Total Liabilities
$4.58M
As of 2025-12-31
$4.98M
As of 2026-06-30
-5.1%
3-year compound annual growth
-3.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.58M | -4.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $4.80M | -9.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $5.28M | -1.5% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $5.36M | +2.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $5.23M | -1.6% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $5.32M | +2.2% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $5.21M | -1.0% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $5.26M | +9.6% | 2020-06-01, Balance as of period end |
| 2017-12-31 | $4.80M | n/a | 2019-04-15, Balance as of period end |
| No annual figure between 2011-12-31 and 2017-12-31. | |||
| 2011-12-31 | $2.11M | -53.4% | 2012-03-16, Balance as of period end |
| 2010-12-31 | $4.54M | n/a | 2012-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $22.84M | -34.9% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
Compare ISCO, BIOA, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗